Nope, no signals from NWBO other than silence and delay. Actually, if there was a recent signal other than the latest 10Q would be of all things Dogood's personal testimony concerning what his mom had to go thru and the doctor's reluctance to have her enter that dcvaxL trial, though the clinical trial site seemed to not be ready anyway. Imuc in its latest conference call stated that they hope to finish making arrangements w/ various cancer organizations in the US and EU to have 120 clinical sites available when the pIII starts later this yr. This sounds very aggressive, but also makes me wonder with NWBO having only 84 sites so far (still that number is better than having only 55 not too long ago and there are more sites now that are active but not recruiting or complete than before) why it took so long to get to this number and why not more earlier. Was it financing that was the issue- maybe. Or did they not go thru the right channels and meet the right person to get the right support from various gbm foundations/centers and support grps and if so why not? Doctors are needed to funnel patients to a prospective clinical trial and it would be unwise to try to go over them and directly to patients. NWBO really needs the cooperation of professionals at various levels and not just the patients. Maybe it will be different in UK and Germany, but I'm thinking there are too many pI/II single arm trials in gbm that are preventing companies from getting enough patients to finish their late stage trials. I would hope that doctors and cancer centers would prioritize sending patients to the later stage trials to get those finished first- but that is jmho.
Concerning the cognate payments per patient ratio that I did, I never intended it to spark this much debate. I only wanted to put into perspective what those expense numbers were in a more meaningful way for comparison purposes. Otherwise numbers can be boring and easily glossed over. But at least thru these debates, I did learn that Direct trials would be more expensive because of the intratumoral injection done by specialists. Having more than one tumor injected will obviously make it more expensive as well and make this not appealing for commercialization purposes. Well for all the longs here, I hope that by end of this month there will be more direct data presented at the ASCO and maybe even an IA PR'd as well. I'm just waiting to see a well designed definitive trial showing cancer vaccines working well enough to be approved and commercially successful to kick this sector into high gear. Like I said before, I had hoped it would be NWBO and IMUC first, but now it seems it may be CLDX but still that is good news for all.
News 
Market Data 
Discover 
AI
